Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

AACR 2021 | Mobocertinib for previously treated NSCLC with EFGR mutations

Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, Fairfax, VA, discusses the use of the tyrosine kinase inhibitor (TKI) mobocertinib in patients with previously treated non-small cell lung cancer (NSCLC) who have EFGR exon 20 insertion mutations. A Phase I/II trial (NCT02716116) of mobocertinib in this patient population reported a preliminary response rate between 26% and 40%. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.